What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Giuseppe Tonini focuses on Internal medicine, Oncology, Colorectal cancer, Cancer and Cancer research.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Endocrinology and Surgery.
The Oncology study combines topics in areas such as Hazard ratio, Survival analysis, Survival rate and FOLFIRI.
His work is dedicated to discovering how Colorectal cancer, Clinical trial are connected with Progression-free survival, Chemotherapy regimen, Placebo and Trastuzumab and other disciplines.
The various areas that Giuseppe Tonini examines in his Cancer study include Prospective cohort study, Pathology, Immunology and Genotype.
Giuseppe Tonini has researched Cancer research in several fields, including Bone metastasis, Breast cancer, Metastasis, Prostate cancer and Cell cycle.
His most cited work include:
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis (1560 citations)
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer (550 citations)
- Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). (506 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Oncology, Cancer, Colorectal cancer and Surgery.
Giuseppe Tonini regularly ties together related areas like Gastroenterology in his Internal medicine studies.
His Lung cancer study in the realm of Oncology connects with subjects such as In patient.
His work deals with themes such as Zoledronic acid, Cancer research, Bone disease and Pathology, which intersect with Cancer.
His research integrates issues of Regimen, Fluorouracil and Phases of clinical research in his study of Colorectal cancer.
His studies deal with areas such as KRAS and Epidermal growth factor receptor as well as Cetuximab.
He most often published in these fields:
- Internal medicine (64.16%)
- Oncology (45.66%)
- Cancer (25.05%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (64.16%)
- Oncology (45.66%)
- Cancer (25.05%)
In recent papers he was focusing on the following fields of study:
Giuseppe Tonini spends much of his time researching Internal medicine, Oncology, Cancer, Colorectal cancer and Chemotherapy.
Giuseppe Tonini merges Internal medicine with In patient in his research.
His Oncology research integrates issues from Bevacizumab, Cetuximab, Nivolumab and Disease.
His work focuses on many connections between Cancer and other disciplines, such as Cancer research, that overlap with his field of interest in Carcinogenesis.
His work in Colorectal cancer covers topics such as Phases of clinical research which are related to areas like Temozolomide.
His research in Chemotherapy intersects with topics in Gastroenterology and Lung.
Between 2016 and 2021, his most popular works were:
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial (228 citations)
- Gut Microbiota and Cancer: From Pathogenesis to Therapy (121 citations)
- Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study (81 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Giuseppe Tonini mainly investigates Internal medicine, Oncology, Cancer, Colorectal cancer and Regimen.
His study in Internal medicine concentrates on Breast cancer, Clinical trial, Prostate cancer, Concomitant and Cancer pain.
His Oncology research is multidisciplinary, incorporating elements of Cetuximab, Nivolumab and Metastatic breast cancer.
His Cancer research is multidisciplinary, relying on both Cancer research, Gut Epithelium, Dysbiosis and Immune system.
In his study, Clinical endpoint, Capecitabine, Metronomic Chemotherapy and Temozolomide is strongly linked to Phases of clinical research, which falls under the umbrella field of Colorectal cancer.
His study in Regimen is interdisciplinary in nature, drawing from both Bevacizumab and FOLFOXIRI.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
